Shares Biotechnology ETF offers efficient, diversified exposure to the sector's revival, balancing risk and cost for ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other ...

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

TCG Labs Soleil’s Juri Biosciences is offering EpimAb Biotherapeutics up to $210 million biobucks for exclusive licensing ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to ...

Merck & Co. is undervalued with strong oncology growth, key R&D investments, and shareholder returns. Click here to read an ...

AbbVie in partnership with the University of Toronto's SpinUp, are pleased to announce Neuropeutics Inc as the recipient of the AbbVie Biotech Innovators Award, a national prize to help foster ...

From my colleague Adam Feuerstein: French drug maker Sanofi is acquiring the small biotech Vigil Neuroscience for $470 ...

Dr. Austin's appointment comes at a transformative period for VERAXA and I’m looking forward to working with him as we enter the next phase in VERAXA’s journey,” commented Christoph Antz, Ph.D., CEO ...

At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.

Discover 9 promising small molecule drug discovery companies that recently raised funding for their potentially breakthrough ...